(NASDAQ:MRNA) today announced that clinical, safety and translational data from its Phase 1/2 study evaluating mRNA-4359 in ...

Moderna’s mRNA-4359, when used with Keytruda, achieves a 24% overall objective response rate in patients with melanoma, with ...

Moderna (MRNA) announced that clinical, safety and translational data from its Phase 1/2 study evaluating mRNA-4359 in combination with ...

UT Southwestern Medical Center researchers have identified two distinct populations of cells known as antigen-presenting ...

UMass Amherst researchers have developed a groundbreaking nanoparticle-based cancer vaccine that prevented melanoma, ...

A next-generation cancer vaccine has shown stunning results in mice, preventing up to 88% of aggressive and ...

A study led by University of Massachusetts Amherst researchers demonstrates that their nanoparticle-based vaccine can ...

Countries straining to contain a second wave of COVID-19 are turning to faster, cheaper but less accurate tests to avoid the delays and shortages that have plagued efforts to diagnose and trace those ...

BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced a new publication in Pregnancy titled, High ...

The United States is once again watching coronavirus cases and hospitalizations rise as summertime nears. Nearly half of Americans – 45 percent – are living in communities with medium or high ...

The Madrid capital region is pressing the Spanish government to allow pharmacies to carry out mass antigen testing for COVID-19, tapping into a broad debate on the efficiency of the rapid tests.